- Nachrichtendetail
-
16.05.2024 07:00:13 - dpa-AFX: GNW-Adhoc: (Ad hoc announcement pursuant to Art. 53 LR) Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity
* Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a
clinically meaningful and statistically significant mean placebo-adjusted
weight loss of 18.8% (p Â
clinically meaningful and statistically significant mean placebo-adjusted
weight loss of 18.8% (p Â
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
ROCHE HLDG AG INH. SF 1 | 851311 | Hamburg | 0,000 | 05.06.24 06:15:00 | ±0,000 | ±0,00% | 0,000 | 0,000 | 0,000 | 245,200 |
